Ablevia develops a new class of infusible therapeutics to selectively remove harmful and disease-causing antibodies. These therapeutics can be readily adapted to target unwanted antibodies in rare diseases or in conditions with unmet clinical needs. Founded in 2018 at the Vienna Biocenter Campus, Ablevia focuses on IP generation and preclinical research and development.
R&D:Ablevia focusses on research and development of therapeutics for the selective removal of disease-causing and harmful anitbodies in autoimmune diseases or neutralizing anti-drug anitbodies.